Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

October 25, 2018 1:11 am

By 

Real-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more

Quality of Life Maintained With Niraparib for Ovarian Cancer

August 1, 2018 9:19 pm

by Madeline Marr

The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.

An international team of researchers led … Read more

Study: Don’t Delay Platinum Re-Challenge in Ovarian Cancer

October 13, 2017 7:57 pm

Don’t delay platinum-based chemotherapy in favor of single-agent non-platinum-based chemotherapy in patients with partially platinum-sensitive ovarian cancer, Italian researchers advised.

Introducing non-platinum chemotherapy to prolong the platinum-free interval (PFI) in patients with progressing ovarian cancer who experience disease recurrence, or … Read more

Knowledge and Good Decision Making Tools for Ovarian Cancer Patients

March 8, 2017 11:00 pm

By: Annette McElhiney

As a retired college professor, I firmly believe that knowledge is power and may also result in a longer healthier life. In a recent Wall Street Journal article, “How to Get Patients to Take More Control Read more

Avastin Gains Expanded FDA Approval for Platinum-Sensitive Ovarian Cancer

December 8, 2016 7:04 pm

Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.

The approval … Read more